1. Home
  2. DLTH vs ACOG Comparison

DLTH vs ACOG Comparison

Compare DLTH & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Duluth Holdings Inc. Class B

DLTH

Duluth Holdings Inc. Class B

HOLD

Current Price

$4.43

Market Cap

138.0M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.00

Market Cap

110.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLTH
ACOG
Founded
1989
2000
Country
United States
Canada
Employees
N/A
57
Industry
Clothing/Shoe/Accessory Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
110.4M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
DLTH
ACOG
Price
$4.43
$8.00
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$7.00
$16.00
AVG Volume (30 Days)
243.8K
36.5K
Earning Date
06-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
64.12
N/A
EPS
N/A
N/A
Revenue
$565,184,000.00
N/A
Revenue This Year
N/A
$139.22
Revenue Next Year
$2.80
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$4.50
52 Week High
$5.09
$10.88

Technical Indicators

Market Signals
Indicator
DLTH
ACOG
Relative Strength Index (RSI) 57.76 76.26
Support Level $2.80 $5.17
Resistance Level $5.09 N/A
Average True Range (ATR) 0.34 0.54
MACD -0.01 0.15
Stochastic Oscillator 46.22 88.89

Price Performance

Historical Comparison
DLTH
ACOG

About DLTH Duluth Holdings Inc. Class B

Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: